Atlas Trials

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)

Clinical trial NCT03496207 · COMPLETED

Trial details

NCT number
NCT03496207
Sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Pulmonary Arterial Hypertension
Start date
2018-06-13
Primary completion
2022-03-09
Enrollment
106

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.